Amber Tong – Page 17 – Endpoints News

about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW

Amber Tong on LinkedIn

author articles

AstraZeneca, Ionis boast full PhIII win for ATTR drug under review

3 years ago

Latest on ultra-rare disease approval; Positive, if mixed, signs for Biogen's ALS drug; Clay Siegall finds a new job; ...

3 years ago

Stuart Peltz resigns as PTC Therapeutics CEO after 25 years

3 years ago

Incyte hit by CRL on extended-release JAK tablets, muddying plans for Jakafi franchise expansion

3 years ago

Hard pressed for cash, Cyclerion looks for help funding rare disease drug

3 years ago

Updated: Ex-Seagen chief Clay Siegall emerges as CEO of private biotech

3 years ago

Sanofi, Regeneron boast PhIII win with Dupixent in COPD, clearing first bar for expansion

3 years ago

Astellas fleshes out more PhIII data for Claudin 18.2 drug

3 years ago

Exclusive: After getting his drug back, Landos founder assembles new startup for the big PhIII test

3 years ago

Who are the women breaking barriers in drug development? Nominate them for Endpoints' annual report

3 years ago

Incyte touts mid-stage data for new JAK inhibitor but stops short of selecting PhIII dose

3 years ago

Sobi's PhIII gout win sets up a potential rivalry with future Amgen asset

3 years ago

Athenex discloses patient death, clinical hold on CAR-NKT trial as it seeks strategic alternatives

3 years ago

Novartis and Biogen pull out of neuro drug partnerships with Sangamo

3 years ago

Seagen goes to Pfizer for $43B; Sanofi buys diabetes partner Provention; Crisis averted in SVB demise; and more

3 years ago

BeiGene decides not to license DKK1 drug, but keeps PD-1 combo trial in gastric cancer

3 years ago

Royalty Pharma nabs $475M milestone from Pfizer upon migraine nasal spray OK

3 years ago

Oral vaccine player lays off 27% of staff as it shelves Covid work

3 years ago

F-star's sale to Chinese buyer cleared by CFIUS following months of holdup

3 years ago

FDA delays review of BioMarin's hemophilia gene therapy after data update

3 years ago

Mental health-focused atai chops 30% of staff to 'further focus' on looming readouts

3 years ago

Red Tree, RA Capital lead $108M infusion into Bicara and its bifunctional I/O drug

3 years ago

Months after reorg, Adaptimmune merges with fellow cell therapy developer

3 years ago

Voyager nabs $25M cash as Novartis runs with two AAV capsids for neuro gene therapy

3 years ago

First page Previous page 14 15 161718 19 20 Next page Last page